ClinicalTrials.gg

Program

Cytarabine

Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.

Furthest: phase 3, since Oct 4, 200032 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis30 open or runningphase 3since Oct 4, 2000Oct 4, 2000none ahead
Vion Pharmaceuticals30 open or runningphase 2since Jul 19, 2006Jul 8, 2003none ahead
Antisoma Research20 open or runningphase 3since Jul 14, 2008Jul 14, 2008none ahead
Boehringer Ingelheim20 open or runningphase 2since Mar 4, 2008Mar 4, 2008none ahead
Hoffmann-La Roche20 open or runningphase 2since Aug 16, 2007Aug 16, 2007none ahead
Moleculin Biotech21 open or runningphase 3since Dec 5, 2024Feb 22, 2022Aug 2029phase 3 · NCT06788756
Theradex20 open or runningphase 2since Oct 3, 2003Jan 27, 2003none ahead
AbbVie10 open or runningphase 3since Aug 10, 2020Aug 10, 2020none ahead
arog-pharmaceuticals-inc10 open or runningphase 2since Oct 18, 2017Oct 18, 2017none ahead
cornerstone-pharmaceuticals10 open or runningphase 3since Apr 12, 2018Apr 12, 2018none ahead
CSPC Pharmaceutical Group10 open or runningphase 2since Oct 19, 2021Oct 19, 2021none ahead
eleos-inc10 open or runningphase 2since Dec 19, 2003Dec 19, 2003none ahead
kanisa-pharmaceuticals10 open or runningphase 2since Aug 9, 2005Aug 9, 2005none ahead
Kura Oncology11 open or runningphase 3since May 16, 2025May 16, 2025Nov 2031phase 3 · NCT07007312
oncovir-inc10 open or runningphase 1since Aug 19, 2020Aug 19, 2020none ahead
Pfizer10 open or runningphase 3since Dec 21, 2017Dec 21, 2017none ahead
polaris-group10 open or runningphase 1since Aug 9, 2016Aug 9, 2016none ahead
Sichuan Biokin Pharmaceutical11 open or runningphase 3since Nov 20, 2025Nov 20, 2025Dec 2027phase 3 · NCT07255872
Stelexis BioSciences11 open or runningphase 1since Jul 24, 2024Jul 24, 2024Dec 15, 2027phase 1 · NCT06533761
Sumitomo Pharma10 open or runningphase 1since Sep 27, 2017Sep 27, 2017none ahead
tarapeutics-science-inc11 open or runningphase 2since Jan 16, 2022Jan 16, 2022none ahead
texas-oncology-cancer-center10 open or runningphase 2since Nov 18, 2011Nov 18, 2011none ahead
xanthus-pharmaceuticals-inc10 open or runningphase 2since Jan 5, 2006Jan 5, 2006none ahead

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Oct 4, 2000.

  1. Aug 9, 2016polaris-group's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to polaris-grouppolaris-group · NCT02875093 · 23 enrolled · Taiwan
  2. Sep 27, 2017Sumitomo Pharma's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
  3. Oct 18, 2017arog-pharmaceuticals-inc's first study: phase 2 study in RecurrenceNew to arog-pharmaceuticals-incarog-pharmaceuticals-inc · NCT03324243
  4. Dec 21, 2017Pfizer's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
  5. Apr 12, 2018cornerstone-pharmaceuticals's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to cornerstone-pharmaceuticalscornerstone-pharmaceuticals · NCT03504410 · 200 enrolled · United States, Australia, Austria and more
  6. Aug 10, 2020AbbVie's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT04509622 · 14 enrolled · Japan
  7. Aug 19, 2020oncovir-inc's first study: phase 1 study in Mesothelioma, MalignantNew to oncovir-inconcovir-inc · NCT04525859 · 19 enrolled · United States
  8. Oct 19, 2021CSPC Pharmaceutical Group's first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05100303 · 58 enrolled · China
  9. Jan 16, 2022tarapeutics-science-inc's first study: phase 2 study in RecurrenceNew to tarapeutics-science-inctarapeutics-science-inc · NCT05241093 · 18 planned · China
  10. Feb 22, 2022Moleculin Biotech's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
  11. Jul 24, 2024Stelexis BioSciences's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Stelexis BioSciencesStelexis BioSciences · NCT06533761 · 105 planned · United States, Spain
  12. Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more
  13. May 16, 2025Kura Oncology's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
  14. Nov 20, 2025Sichuan Biokin Pharmaceutical's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
  2. Dec 15, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteStelexis BioSciences · NCT06533761
  3. Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756
  4. Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07255872Leukemia, Myeloid, Acute · China3RecruitingSichuan Biokin PharmaceuticalDec 2027216
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingKura OncologyNov 20311,300
NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more3RecruitingMoleculin BiotechAug 2029312
NCT06533761Leukemia, Myeloid, Acute · United States, Spain1RecruitingStelexis BioSciencesDec 15, 2027105
NCT05319587Leukemia, Myeloid, Acute · Italy, Poland2CompletedMoleculin BiotechAug 2, 202322
NCT05241093Recurrence · China2Recruitingtarapeutics-science-incDec 30, 202518
NCT05100303Recurrence · China2UNKNOWNCSPC Pharmaceutical GroupNov 202258
NCT04525859Mesothelioma, Malignant · United States1Completedoncovir-incJun 18, 202519
NCT04509622Leukemia, Myeloid, Acute · Japan3CompletedAbbVieApr 15, 202114
NCT03504410Leukemia, Myeloid, Acute · United States, Australia, Austria and more3Terminatedcornerstone-pharmaceuticalsOct 25, 2021200
NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more3CompletedPfizerJun 5, 2020730
NCT03324243Recurrence2Withdrawnarog-pharmaceuticals-incDec 20200
NCT03298984Leukemia, Myeloid, Acute · United States1CompletedSumitomo PharmaMar 20, 202032
NCT02875093Leukemia, Myeloid, Acute · Taiwan1Terminatedpolaris-groupJul 10, 201923
NCT01773408Leukemia, Myeloid, Acute · United States, Australia, Canada and more1CompletedHoffmann-La RocheJun 2016122
NCT01500161Leukemia, Myeloid, Acute · United States2Terminatedtexas-oncology-cancer-centerNov 20131
NCT01066494Leukemia, Myeloid, Acute · Georgia, Ukraine2UNKNOWNAntisoma ResearchSep 201020
NCT00804856Leukemia, Myeloid, Acute · Austria, Belgium, Canada and more2CompletedBoehringer IngelheimMar 9, 2012180
NCT00715637Leukemia · United States, Argentina, Australia and more3UNKNOWNAntisoma ResearchJun 2010420
NCT00632749Leukemia, Myeloid, Acute · Germany2CompletedBoehringer IngelheimMar 201468
NCT00517699Lymphoma · Canada2TerminatedHoffmann-La RocheMar 20095
NCT00354276Leukemia · United States, France, United Kingdom2UNKNOWNVion PharmaceuticalsDec 200885
NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more3CompletedNovartisMar 20121,106
NCT00273884Leukemia, Myeloid, Acute · United States, Canada2Completedxanthus-pharmaceuticals-inc80
NCT00129168Leukemia, Myeloid2Completedkanisa-pharmaceuticalsMar 2008100
NCT00093600Leukemia, Myeloid, Acute · United States, Germany1CompletedNovartisJun 201169
NCT00074737Leukemia, Myeloid, Acute · United States2Completedeleos-incMay 200753
NCT00070538Leukemia · United States1CompletedVion PharmaceuticalsSep 2004
NCT00069966Lymphoma · United States, Puerto Rico2UNKNOWNTheradex
NCT00064090Leukemia · United States1CompletedVion PharmaceuticalsSep 2004
NCT00053105Lymphoma · United States1UNKNOWNTheradex
NCT00006343Leukemia · United States3CompletedNovartisMar 2007

How it is read

Names in the registry

  • “Cytarabine”, 15 entries
  • “cytarabine”, 8 entries
  • “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
  • “Cytarabine (Ara-C)”, 1 entry
  • “Eganelisib in combination with cytarabine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.